tirzepatide availability fda vs. Semaglutide: What You Should Know Compounded Semaglutide & Tirzepatide 2025:
Description
10.2337/diabetes.51.2007.s434 [DOI] [PubMed] 57.Park S, Dong X, Fisher TL, et al
By 2021, the STEP program tested semaglutide at a higher 2.4mg dose for obesity, and it resulted in around 15% body-weight loss
It means more energy, better mood, and long-term weight control that lasts
Lancet Diabetes Endocrinol 2022;10:741760 [DOI] [PubMed] [Google Scholar] 2
Tirzepatide, the active ingredient in Zepbound and Mounjaro, is part of new class of medications used to treat obesity and diabetes that have skyrocketed in popularity, driving shortages and leading some people to use versions made by compounding pharmacies
